Evidence map›Paper›PMID 40237535›Full record

ArticleThe Laryngoscope2025

Effect of Serial Intralesional Steroid Injections on Risk of Recurrence in Idiopathic Subglottic Stenosis.

Shengjie Ying, Peter Y F Zeng, Kevin Fung, Halema Khan, Matthew J Cecchini, Patrick MacInnis, Jennifer Anderson, Amir H Karimi, MohdWessam Al Jawhri, Harrison Pan and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07654517 (A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07654517 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2026 to 2029Enrolled40ConditionsIdiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)ArmsPirfenidone 267 MG [Esbriet], Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shengjie YingDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.ORCID https://orcid.org/0009-0008-3094-3129
Peter Y F ZengDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Kevin FungDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Halema KhanDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Matthew J CecchiniDepartment of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
Patrick MacInnisDepartment of Otolaryngology-Head & Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Unity Health Toronto-St. Michael's Hospital, Toronto, Ontario, Canada.
Jennifer AndersonDepartment of Otolaryngology-Head & Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Unity Health Toronto-St. Michael's Hospital, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-7080-9567
Amir H KarimiDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
MohdWessam Al JawhriDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Harrison PanDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Nhi LeDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Krista JorisDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Joe S MymrykDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Vanessa DumeauxDepartment of Oncology, Western University, London, Ontario, Canada.
John W BarrettDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
Anthony C NicholsDepartment of Otolaryngology-Head & Neck Surgery, Western University, London, Ontario, Canada.
R Jun LinDepartment of Otolaryngology-Head & Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Unity Health Toronto-St. Michael's Hospital, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-1064-5868
Canadian Airways Research Group of the Canadian Society of Otolaryngology Collaborative Research Initiative

Funding

Academic Medical Organization of Southwestern Ontario INN21-016American Laryngological Association 1082Canadian Institute of Heath Research Canada Graduate Scholarship-DoctoralDepartment of Otolaryngology-Head and Neck Surgery at University of Toronto and Western UniversityWolfe Surgical Research Professorship in the Biology of Head and Neck Cancers
6 · The paper itself

Abstract

backgroundSerial intralesional steroid injections (ILSIs) have been suggested to be an effective adjunct treatment for idiopathic subglottic stenosis (iSGS) by maintaining airway patency and extending inter-surgical intervals. However, evidence for the effectiveness of serial ILSIs remains inconclusive. The current study aimed to assess whether ILSIs reduce the risk of subsequent surgical dilation (i.e., recurrence) in a cohort of patients with iSGS.

methodsProspectively collected clinical data for 75 female iSGS patients with 1-4 years of follow-up were analyzed. To assess the effect of ILSI use on the risk of recurrence, we assessed both the time-to-first recurrence using a standard Cox proportional hazards model and all recurrences per patient using a recurrent-events model. Overall, there were 36 patients who had received ILSIs at any point in the follow-up period and 39 patients who had not.

resultsILSI use was associated with a significantly reduced risk of recurrence in both time-to-first event (hazard ratio (HR) = 0.20, 95% confidence interval (CI) 0.08-0.49) and recurrent events (HR = 0.44, 95% CI 0.26-0.75) multivariate Cox proportional hazard models, along with older age at diagnosis and longer time since diagnosis (all p < 0.05). In the time-to-first event analysis, the median time to recurrence among those who had received ILSIs was 2.5 years compared to 1.4 years among those who had not. The number needed to treat with ILSIs to avoid one recurrence by 2 years follow-up was two.

conclusionSerial ILSIs were associated with reduced risk of recurrence, along with older age at diagnosis and longer time since diagnosis. LEVEL OF EVIDENCE: 3 (non-randomized controlled cohort/follow-up study).

Indexed as

GlucocorticoidsLaryngostenosisAdultAgedFemaleFollow-Up StudiesHumansInjections, IntralesionalMiddle AgedProportional Hazards ModelsProspective StudiesRecurrenceTreatment OutcomeGlucocorticoidscox regressionendoscopic surgical dilationidiopathic subglottic stenosis (iSGS)recurrenceserial intralesional steroid injections

Identifiers

PMID40237535
PMCPMC12371796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.